Phase I, double-blind, randomised, placebo-controlled crossover in healthy volunteers (n=25) comparing inhaled DMT 60 mg with a 1 mg placebo-like inhalation across two sessions on the same day.
Randomised, double-blind, placebo-controlled crossover assessing acute and subacute effects of inhaled N,N‑Dimethyltryptamine in healthy adults; each participant receives two inhalation sessions (DMT 60 mg and placebo-like 1 mg) the same day.
Primary focus is safety and tolerability with monitoring of vital signs, respiratory status, adverse events, and clinical assessments at acute and follow-up timepoints.
Single inhaled dose of vaporized DMT 60 mg.
Vaporized DMT, single-session.
Single inhaled dose of very low-dose DMT (placebo-like, 1 mg).
Placebo-like inhalation containing 1 mg DMT.